1. Co-expression of VEGF-B and FLT-1 correlates with malignancy and prognosis of gastric cancer
- Author
-
Longlong Liu, Wei Bi, Yanpeng Ma, Wenyao Wang, and Yang Liu
- Subjects
Male ,0301 basic medicine ,Oncology ,Vascular Endothelial Growth Factor B ,medicine.medical_specialty ,Poor prognosis ,Angiogenesis ,VEGF receptors ,medicine.medical_treatment ,Clinical Biochemistry ,Malignancy ,Targeted therapy ,03 medical and health sciences ,0302 clinical medicine ,Stomach Neoplasms ,Internal medicine ,Drug Discovery ,Biomarkers, Tumor ,medicine ,Overall survival ,Humans ,Rank correlation ,Vascular Endothelial Growth Factor Receptor-1 ,biology ,business.industry ,Biochemistry (medical) ,Cancer ,Middle Aged ,Prognosis ,equipment and supplies ,medicine.disease ,Survival Rate ,030104 developmental biology ,030220 oncology & carcinogenesis ,embryonic structures ,cardiovascular system ,biology.protein ,Female ,sense organs ,business ,circulatory and respiratory physiology - Abstract
Background: This study aims to investigate the correlation of VEGF-B and FLT-1 co-expression with the prognosis of gastric cancer (GC). Materials & methods: Primary GC samples and adjacent tissues were obtained from 96 patients. Results: Both VEGF-B and FLT-1 were testified to be upregulated in the human GC compared with adjacent tissues. Spearman’s rank correlation analysis indicated that VEGF-B and FLT-1 expression were correlated (r = 0.321, p = 0.0015). High VEGF-B and FLT-1 co-expression patients showed poor prognosis when compared with low VEGF-B and FLT-1 co-expression patients (p = 0.0169). Conclusion: The high co-expression of VEGF-B and FLT-1 in GC shows a poor prognosis of overall survival, and targeted therapy against the interaction between VEGF-B and FLT-1 is worth further detailed analysis.
- Published
- 2021